Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

Antonios Likourezos · NCT05227937

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 14–110 · Women only
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
75
US sites recruiting
1
Study start
September 21, 2022
Record last updated
September 11, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, and then take antibiotics for 3-7 days. A single dose of amikacin has been demonstrated to be safe, effective and well tolerated in other studies, but some patients may decline to participate because they do not wish to have an IV or IM shot, or because they don't want to speak on the phone with a research assistant three times over the next 30 days.

Being studied: Amikacin

Conditions: Urinary Tract Infections

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • female emergency medicine patients
  • ≥14 years of age
  • uncomplicated urinary tract infection
  • a primary urinary complaint and nitrite-positive urine.

Exclusion Criteria

  • pregnancy
  • abnormal genitourinary tract
  • recent urinary tract instrumentation
  • immunosuppression
  • CrCl \< 25 mL/min
  • evidence of pyelonephritis or sepsis
  • any antibiotic treatment within 30 days
  • not available for phone follow-up in 3, 7, and 30 days
  • requires admission to the hospital
  • abnormal mental status.

Recruiting US locations

  • Maimonides Medical Center

    Brooklyn, NY 11219

    Site contact: Reuben Strayer, MD · rstrayer@maimonidesmed.org

Study contacts (from the official record)

  • Reuben Strayer, MD · 718-283-6000 · rstrayer@maimonidesmed.org
  • Antonios Likourezos, MA, MPH · 718-283-6896 · alikourezos@maimonidesmed.org
All healthy volunteers studies in New York →
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A… (NCT05227937) | Bored Studies